Blood Test Stocks Surge 26% in 6 Trading Days... 2 Trillion Won Added Today

Guardant Health Inc. (Nasdaq: GH) surged 8.2% on May 27, closing at $129.68 and lifting its market capitalization to about $17.1 billion. Over the course of the day, its market value rose by roughly $1.5 billion, with 2.63 million shares changing hands amid strong demand.

The stock has extended its recent rally, building on a cumulative 26% gain over the past six trading days. Analysts attribute the momentum to the company’s early-May release of first-quarter 2026 results—alongside an upward revision to full-year revenue guidance—and to the inclusion of its Shield colorectal cancer blood test in American Cancer Society guidelines, as well as early FDA approval for its Guardant360 assay, all of which have heightened growth expectations.

Headquartered in Palo Alto, California, Guardant Health is a precision oncology diagnostics firm that utilizes liquid biopsy technology to analyze circulating tumor DNA in the bloodstream, providing cancer detection and treatment-response monitoring services. Its flagship products—Guardant360 and the Shield early colorectal cancer test—are FDA-approved and employed as companion diagnostics across multiple solid tumor types, positioning the company as a global leader in the liquid biopsy market.